7 Results for "

bone lesions

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "bone lesions" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-18664
CAS No.: 900305-37-5
Research Areas:  

Cancer

PFI-4 (compound 11), a chemical probe, is a potent and highly selective BRPF1 Bromodomain (BRPF1B) inhibitor, with an IC50 of 172 nM. PFI-4 can be used to explore the functional mechanisms of the HBO1/BRPF1 complex and to study bone loss and osteolytic malignant bone lesions .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99590
CAS No.: 1001080-50-7
Synonyms: ACE-011; MK-7962
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .
loading...
    loading...
Cat. No.: HY-P5362
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
loading...
    loading...
Cat. No.: HY-W008951
CAS No.: 1429-50-1
Synonyms: EDTMP
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers .
loading...
    loading...
Cat. No.: HY-P990552A

Target:  

PAI-1 Integrin

Research Areas:  

Cancer

huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .
loading...
    loading...
Cat. No.: HY-181696
CAS No.: 1025066-50-5
Target:  

PSMA

Research Areas:  

Cancer

EC0652 is a PSMA imaging agent with SPECT imaging capability. EC0652 can be used for the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-P992475

Research Areas:  

Cancer

Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977) .
loading...
    loading...